Free Trial

BioNTech (BNTX) Stock Forecast & Price Target

$85.46
-0.91 (-1.05%)
(As of 07/19/2024 ET)

BioNTech - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 10 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Hold." Out of the 10 analysts, 1 has given a sell rating, 6 have given a hold rating, and 3 have given a buy rating for BNTX.

Consensus Price Target

$111.70
30.70% Upside
High Forecast$171.00
Average Forecast$111.70
Low Forecast$90.00

According to the 10 analysts' twelve-month price targets for BioNTech, the average price target is $111.70. The highest price target for BNTX is $171.00, while the lowest price target for BNTX is $90.00. The average price target represents a forecasted upside of 30.70% from the current price of $85.46.

TypeCurrent Forecast
7/22/23 to 7/21/24
1 Month Ago
6/22/23 to 6/21/24
3 Months Ago
4/23/23 to 4/22/24
1 Year Ago
7/22/22 to 7/22/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
7 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$111.70$111.70$120.40$166.60
Forecasted Upside30.70% Upside17.94% Upside26.01% Upside32.47% Upside
Get BioNTech Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioNTech Stock vs. The Competition

TypeBioNTechMedical CompaniesS&P 500
Consensus Rating Score
2.20
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside30.70% Upside3,283.13% Upside10.07% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/26/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$113.00 ➝ $113.00+33.92%
5/14/2024Evercore ISI
2 of 5 stars
C. Kasimov
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageInline$100.00+7.85%
5/7/2024TD Cowen
4 of 5 stars
 Boost TargetHold ➝ Hold$95.00 ➝ $98.00+7.76%
5/7/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$123.00 ➝ $122.00+32.90%
3/27/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$110.00 ➝ $101.00+8.73%
3/22/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$99.00 ➝ $90.00-1.59%
3/21/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$171.00+87.66%
2/28/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$113.00 ➝ $100.00+8.80%
1/5/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform
11/8/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$110.00 ➝ $111.00+11.70%
10/16/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$124.00 ➝ $111.00+7.16%
5/18/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$135.00 ➝ $120.00+14.12%
5/17/2023Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$165.00 ➝ $170.00+60.98%
3/28/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Zhiqiang Shu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$260.00+111.38%
3/28/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Akash Tewari
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$145.00+17.31%
3/27/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$239.00 ➝ $194.00+56.96%
8/17/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$177.00+10.37%
7/29/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Daina Graybosch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform$223.00 ➝ $224.00+35.82%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:50 AM ET.

BNTX Forecast - Frequently Asked Questions

What is BioNTech's forecast for 2024?

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $111.70, with a high forecast of $171.00 and a low forecast of $90.00.

Should I buy or sell BioNTech stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There is currently 1 sell rating, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares.

Does BioNTech's stock price have much upside?

According to analysts, BioNTech's stock has a predicted upside of 20.07% based on their 12-month stock forecasts.

What analysts cover BioNTech?

BioNTech has been rated by research analysts at BMO Capital Markets, Evercore ISI, HC Wainwright, and TD Cowen in the past 90 days.

Do Wall Street analysts like BioNTech more than its competitors?

Analysts like BioNTech less than other "medical" companies. The consensus rating for BioNTech is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BNTX compares to other companies.


This page (NASDAQ:BNTX) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners